Neurocrine Biosciences Reveals Key Insights on INGREZZA® Through New Comprehensive Review in CNS Spectrums Neurocrine Biosciences has published a crucial review in CNS Spectrums highlighting the unique features of INGREZZA®, a VMAT2 inhibitor for tardive dyskinesia.

Neurocrine Biosciences Reveals Key Insights on INGREZZA® Through New Comprehensive Review in CNS Spectrums #USA #San_Diego #Neurocrine_Biosciences #INGREZZA #VMAT2_Inhibitors

Neurocrine Biosciences Reveals Insights on VMAT2 Inhibitors in Tardive Dyskinesia Treatment Neurocrine Biosciences showcases real-world data confirming that all patients using INGREZZA achieve therapeutic doses unlike deutetrabenazine. Key findings will be shared at the upcoming pharmacy meeting.

Neurocrine Biosciences Reveals Insights on VMAT2 Inhibitors in Tardive Dyskinesia Treatment #United_States #Houston #Neurocrine #INGREZZA #VMAT2_Inhibitors